Search the Newsreel

MapLight shares sink on mixed ph. 2 schizophrenia readout

MapLight Therapeutics' shares plummeted over 60% after revealing mixed results from its phase 2 Zephyr trial for schizophrenia treatment ML-007C-MA. While a twice-daily dose met its primary endpoint by significantly reducing disease severity, a once-daily dose did not achieve statistical significance, although it showed …

Maplight Therapeutics (NASDAQ:MPLT) Shares Down 9.2% - What's Next?

Maplight Therapeutics (NASDAQ:MPLT) saw its shares drop by 9.2% to $13.64 with high trading volume. This decline follows the company reporting a quarterly loss of $1.34 per share, missing analyst estimates. Despite the drop and mixed insider trading activity, the stock maintains an average …

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of "Buy" from Analysts

Maplight Therapeutics, Inc. (NASDAQ:MPLT) has received an average "Buy" recommendation from seventeen research firms, with most analysts issuing buy or strong-buy ratings, despite some recent downward adjustments to price targets. The company's shares opened at $15.02, with a market capitalization of $640.12 million, and …

Maplebear stock may move 9.2% on earnings release

Maplebear Inc. (CART) stock is projected to move by 9.2% following its upcoming earnings release on August 6, according to options data analyzed by Bloomberg. Historically, the actual price movement has exceeded the options-implied move in three out of the last eight earnings announcements. …

Maplebear Number of Employees 2026 | Employee Count & Headcount Data

Maplebear, Inc. (CART) had approximately 3,938 employees worldwide as of March 2026, marking a 5.5% growth from 2023, though a 2.2% decline year-over-year in 2026. The company is actively hiring with 1,205 job postings in 2026, a 64% decline from 2025. Its workforce is …

Mapletree Pan Asia Commercial Trust Secures S$150 Million Facility With Manager-Linked Covenants

Caplin Point Laboratories Q1 Results: Earnings call scheduled for Aug 12

Maple Leaf Foods (TSX:MFI) Attracts Consumer Staples Interest

Maplebear (CART) Earnings Expected to Grow: Should You Buy?

Maplebear (CART) Could Be 23% Overvalued On Its UK Caper Trolley Debut

Maplebear (Instacart) has launched AI-powered Caper smart trolleys in a UK Morrisons supermarket, marking its first international retail deployment. While the company shows mixed stock performance with recent revenue growth, a narrative suggests it is 23.4% overvalued at $37 per share compared to its …

MapLight CEO on what investors missed in the biotech’s schizophrenia data

MapLight Therapeutics CEO Christopher Kroeger expressed surprise at the market's negative reaction to their schizophrenia drug data, which led to a two-thirds drop in market value despite positive results. He argues that investors are overly focused on a direct comparison of PANSS scores with …

Maplebear Chief Legal Officer Morgan Fong Sells 18,390 Shares for $815,400

Morgan Fong, Chief Legal Officer of Maplebear (Instacart), sold 18,390 shares for $815,400 after exercising stock options. This transaction was part of a pre-planned trading strategy and represents a small portion of Fong's total holdings, indicating it's likely for personal reasons rather than a …

Mapletree Logistics Trust (SGX:M44U) Stock Can Margins Offset DPU Strain

ADAR1 Capital Management LLC Purchases New Position in Maplight Therapeutics, Inc. $MPLT

ADAR1 Capital Management LLC has acquired a new position in Maplight Therapeutics, Inc. (NASDAQ:MPLT), purchasing 374,909 shares valued at approximately $7.6 million. This move comes as Maplight Therapeutics faces mixed trial results for its ML-007C-MA drug, with the twice-daily dose showing promise but the …

Maplight Therapeutics (NASDAQ:MPLT) Shares Up 18.2% Following Insider Buying Activity

Mapletree Industrial Trust (SGX:ME8U) Reports Softer Quarterly Earnings, Is It Still Cheap?

Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $148,702.40 in Stock

Maplight Therapeutics Director Troy Cox purchased 15,620 shares of the company's stock for $148,702.40 on July 28, 2026, increasing his ownership significantly. This insider acquisition comes as Maplight shares rose 24.3%, despite recent negative news regarding a trial setback and a quarterly loss. The …

Instacart’s UK Smart Trolley Debut With Morrisons Might Change The Case For Investing In Maplebear (CART)

Instacart (Maplebear) has launched AI-powered Caper smart trolleys at a Morrisons store in the UK, marking its first international retail partnership for this technology. This initiative demonstrates Instacart's strategy to expand its Connected Stores technology globally and integrate online personalization, budgeting tools, and retail …

MapLight Therapeutics recovers a portion of Monday's 73% rout (MPLT:NASDAQ)

MapLight Therapeutics (MPLT) saw its shares rise 23% on Wednesday, partially recovering from a 73% drop the previous day. The initial collapse was due to mixed Phase 2 results for its schizophrenia drug candidate. The company focuses on central nervous system disorders.

Maplight Therapeutics (NASDAQ:MPLT) Sees Unusually-High Trading Volume - Time to Buy?

Maplight Therapeutics (NASDAQ:MPLT) experienced an unusually high trading volume, with shares surging by 982% following positive Phase 2 ZEPHYR trial results for its schizophrenia treatment ML-007C-MA. Despite a consensus "Buy" rating and a target price of $34.42 from analysts, the company recently missed quarterly …

HC Wainwright Issues Pessimistic Forecast for Maplight Therapeutics (NASDAQ:MPLT) Stock Price

HC Wainwright has lowered its price target for Maplight Therapeutics (NASDAQ:MPLT) to $26 from $45, while retaining a "buy" rating, indicating a potential 162.63% upside despite the stock opening down 72.9% at $9.90. The company recently reported a quarterly EPS loss of $1.34, missing …

Instacart's Smart Trolleys are Now Available at Morrisons Preston in the UK

Launching in Preston, Morrisons is the first UK retailer to deploy Instacart's AI-powered Caper smart trolleys SAN FRANCISCO and BRADFORD, England, July 28, 2026 /PRNewswire/ -- Instacart (NASDAQ: CART), the leading grocery technology company in North America, and Morrisons, one of the UK's largest …

Morgan Stanley Downgrades MapLight Therapeutics to Equalweight From Overweight, $34 PT

Morgan Stanley has downgraded MapLight Therapeutics (MPLT) from Overweight to Equalweight, setting a price target of $34. This decision comes after recent news regarding the company, including a significant drop in share price following the failure of its schizophrenia drug in a once-daily test, …

Morgan Stanley Reaffirms "Equal Weight" Rating for Maplight Therapeutics (NASDAQ:MPLT)

Does MapLight Therapeutics’ (MPLT) Dual Symptom And Cognitive Data Hint At A Differentiated Schizophrenia Strategy?

Top Midday Decliners

MapLight Therapeutics' (MPLT) shares tumbled 68% even after the company said its phase 2 trial of ML PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade …

MapLight dives despite positive data for schizophrenia drug

MapLight Therapeutics shares fell by 66% after releasing Phase 2 study results for a schizophrenia drug, despite the data showing positive results regarding general safety and efficacy. Investors were reportedly concerned that the drug's efficacy profile would not be competitive with Bristol Myers Squibb's …

Asset Plus Limited Revenue Breakdown – NZX:APL

MapLight Therapeutics Says Phase 2 Schizophrenia Trial Meets Primary Endpoint

MapLight Therapeutics announced that its Phase 2 trial for a new schizophrenia treatment successfully met its primary endpoint. This positive outcome indicates potential progress in developing novel therapies for schizophrenia, building on the company's research efforts.

MapLight Reports Results From Phase 2 ZEPHYR Trial Of ML-007C-MA; Stock Down More Than 60%

(RTTNews) - MapLight Therapeutics (MPLT) announced positive topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA in adults with an acute exacerbation of schizophrenia. The trial met its primary endpoint, with the 210/3 mg twice-daily dose demonstrating a statistically significant and clinically meaningful …

MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data (MPLT:NASDAQ)

MapLight Therapeutics (MPLT) stock dropped 50% in premarket trading despite positive Phase 2 trial results for its schizophrenia drug candidate. The decline was due to the once-daily dosing regimen failing to achieve statistical significance on the primary endpoint, although the trial did meet its …

MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia, meeting its primary endpoint with a statistically significant improvement in PANSS total score at the 210/3 mg BID dose. The trial also showed significant improvements in cognitive performance …

MapLight Therapeutics (Nasdaq: MPLT) hits key Phase 2 goal in schizophrenia

MapLight Therapeutics announced positive topline results for its Phase 2 ZEPHYR trial of ML-007C-MA in adults with acute exacerbation of schizophrenia. The 210/3 mg twice-daily dose met the primary endpoint with a statistically significant reduction in PANSS total score and showed clinically meaningful improvement …

MapLight Therapeutics Inc (MPLT) Cash Flow

This article provides MapLight Therapeutics Inc (MPLT) cash flow statement data for FY2026Q1, including operating, investing, and financing cash flows. It breaks down key financial metrics, such as a -51.18M operating cash flow and a 67.01M investing cash flow, and offers FAQs explaining cash …

MPLT|MapLight Therapeutics Inc|Price:11.550|Chg%:-0.030

MPLT|MapLight Therapeutics Inc|Price:11.980|Chg%:-0.200